| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9313349 | Urology | 2005 | 6 Pages |
Abstract
The results of our study have shown that DTX is comparatively active for heavily pretreated patients with PTX-resistant HRPC. However, given the significant toxicities and small subject population, well-designed Phase I-II trials of the improved regimen are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Shinji Urakami, Tateki Yoshino, Nobuyuki Kikuno, Shin Imai, Satoshi Honda, Tatuaki Yoneda, Hirofumi Kishi, Kazushi Shigeno, Hiroaki Shiina, Mikio Igawa,